These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21130746)

  • 1. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational insights into the development of novel therapeutic strategies for Alzheimer's disease.
    Prabhakar R
    Future Med Chem; 2009 Apr; 1(1):119-35. PubMed ID: 21426072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
    Dejaegere T; de Strooper B
    Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 7. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.
    Asai M; Iwata N; Tomita T; Iwatsubo T; Ishiura S; Saido TC; Maruyama K
    J Neurosci Res; 2010 Dec; 88(16):3588-97. PubMed ID: 20890992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
    Abe K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs targeting Alzheimer's disease: some things old and some things new.
    Michaelis ML
    J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
    Yan R; Bienkowski MJ; Shuck ME; Miao H; Tory MC; Pauley AM; Brashier JR; Stratman NC; Mathews WR; Buhl AE; Carter DB; Tomasselli AG; Parodi LA; Heinrikson RL; Gurney ME
    Nature; 1999 Dec; 402(6761):533-7. PubMed ID: 10591213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of arylquinones as BACE1 inhibitors, β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils.
    Ortega A; Rincón Á; Jiménez-Aliaga KL; Bermejo-Bescós P; Martín-Aragón S; Molina MT; Csákÿ AG
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2183-7. PubMed ID: 21441028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-secretase: a complex target for Alzheimer's disease.
    Lundkvist J; Näslund J
    Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.